PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33149608-8 2020 Conversely, RNF126 overexpression downregulated p53 and p21 but promoted pRb expression, which was reversed by a classic proteasome inhibitor, MG132. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 143-148 tumor protein p53 Homo sapiens 48-51 34002651-8 2021 Our results showed that MG132 downregulated the expression of antiapoptotic proteins, including CDK2, CDK4, Bcl-xL, and Bcl-2, whereas it upregulated the expression of proapoptotic proteins, including p21, p27, p53, p-p53 (ser15, ser20, and ser46), cleaved forms of caspase-3, caspase-7, caspase-9, and PARP, and FOXO3 in U2OS cells. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 24-29 tumor protein p53 Homo sapiens 211-214 34002651-8 2021 Our results showed that MG132 downregulated the expression of antiapoptotic proteins, including CDK2, CDK4, Bcl-xL, and Bcl-2, whereas it upregulated the expression of proapoptotic proteins, including p21, p27, p53, p-p53 (ser15, ser20, and ser46), cleaved forms of caspase-3, caspase-7, caspase-9, and PARP, and FOXO3 in U2OS cells. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 24-29 tumor protein p53 Homo sapiens 218-221 31954175-7 2020 SKi also enhanced the stimulatory effect of the proteasome inhibitor, MG132 on the expression of the pro-survival protein XBP-1s and this was reduced by siRNA knockdown of SK2 and increased by knockdown of p53. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 70-75 tumor protein p53 Homo sapiens 206-209 31563647-5 2019 Notably, administration of proteasome inhibitor MG132 significantly inhibited the expression of cullin7 and up-regulated the expression of p53 in pulmonary arteries concomitantly with improvement of hypoxia-induced pulmonary vascular remodeling. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 48-53 tumor protein p53 Homo sapiens 139-142 30274821-0 2018 Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 45-51 tumor protein p53 Homo sapiens 106-109 30935019-5 2019 ZNF143 knockdown affected the stability of p53, which showed a dependence on MG132, a proteasome inhibitor. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 77-82 tumor protein p53 Homo sapiens 43-46 32123827-7 2019 The proteasome inhibitor MG132 stabilized p53(DeltaCp44), particularly in mock-infected cells. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 25-30 tumor protein p53 Homo sapiens 42-45 30274821-11 2018 Nutlin-3 combined with MG-132 narrowed this between-group difference and triggered stronger inhibitory effects on the growth of schwannomas through coordinated reactivation of p53. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 23-29 tumor protein p53 Homo sapiens 176-179 28446729-7 2017 The administration of MG132, a proteasome inhibitor, or knockdown of ubiquitin-specific peptidase 9, X-linked (USP9X) both eliminated the effect of WP1130 in decreasing p53 expression. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 22-27 tumor protein p53 Homo sapiens 169-172 28749203-8 2018 R175H p53 expression was rescued by addition of proteasome inhibitor MG132 to CB002, suggesting a role for ubiquitin-mediated degradation of the mutant protein. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 69-74 tumor protein p53 Homo sapiens 6-9 30091530-5 2018 SAHA and MG132 treatment increased the expression levels of ING5, PTEN, p53, Caspase-3, Bax, p21, and p27 but decreased the expression levels of 14-3-3, MMP-2, MMP-9, ADFP, Nanog, c-myc, CyclinD1, CyclinB1, and Cdc25c concentration dependently, similar to ING5. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 9-14 tumor protein p53 Homo sapiens 72-75 29899847-7 2018 HSP90 inhibitors suppressed ubiquitination processes which were involved in p53 degradation, but a proteasome inhibitor, MG-132, prevented the HSP90 inhibitors-induced p53 down-regulation. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 121-127 tumor protein p53 Homo sapiens 168-171 28765903-12 2017 Under the same condition, p53 protein expression, but not mRNA expression, was reversed by MG132. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 91-96 tumor protein p53 Homo sapiens 26-29 27766434-0 2017 MG132 plus apoptosis antigen-1 (APO-1) antibody cooperate to restore p53 activity inducing autophagy and p53-dependent apoptosis in HPV16 E6-expressing keratinocytes. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 0-5 tumor protein p53 Homo sapiens 69-72 28220348-7 2017 The resulted showed that MG132 induced significant apoptosis, and caused the accumulation of p53 protein in both p53 wild-type and mutant-type thyroid cancer cell lines, whereas the proapoptotic targets of p53 were transcriptionally upregulated only in the p53 wild-type cells. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 25-30 tumor protein p53 Homo sapiens 93-96 28220348-7 2017 The resulted showed that MG132 induced significant apoptosis, and caused the accumulation of p53 protein in both p53 wild-type and mutant-type thyroid cancer cell lines, whereas the proapoptotic targets of p53 were transcriptionally upregulated only in the p53 wild-type cells. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 25-30 tumor protein p53 Homo sapiens 113-116 28220348-7 2017 The resulted showed that MG132 induced significant apoptosis, and caused the accumulation of p53 protein in both p53 wild-type and mutant-type thyroid cancer cell lines, whereas the proapoptotic targets of p53 were transcriptionally upregulated only in the p53 wild-type cells. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 25-30 tumor protein p53 Homo sapiens 113-116 28220348-7 2017 The resulted showed that MG132 induced significant apoptosis, and caused the accumulation of p53 protein in both p53 wild-type and mutant-type thyroid cancer cell lines, whereas the proapoptotic targets of p53 were transcriptionally upregulated only in the p53 wild-type cells. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 25-30 tumor protein p53 Homo sapiens 113-116 27766434-7 2017 Inhibition of E6-mediated p53 proteasomal degradation by MG132 resulted in the elevation of p53 protein levels and its phosphorylation in Ser46 and Ser20; the p53 protein was localized mainly at nucleus after treatment with MG132 or APO-1 plus MG132. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 224-229 tumor protein p53 Homo sapiens 92-95 27766434-7 2017 Inhibition of E6-mediated p53 proteasomal degradation by MG132 resulted in the elevation of p53 protein levels and its phosphorylation in Ser46 and Ser20; the p53 protein was localized mainly at nucleus after treatment with MG132 or APO-1 plus MG132. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 224-229 tumor protein p53 Homo sapiens 92-95 27993609-8 2017 The downregulation of p53 levels induced by CPF was partially blocked when cells were exposed to CPF in the presence of the proteasome inhibitor MG132. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 145-150 tumor protein p53 Homo sapiens 22-25 27766434-7 2017 Inhibition of E6-mediated p53 proteasomal degradation by MG132 resulted in the elevation of p53 protein levels and its phosphorylation in Ser46 and Ser20; the p53 protein was localized mainly at nucleus after treatment with MG132 or APO-1 plus MG132. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 224-229 tumor protein p53 Homo sapiens 26-29 27766434-0 2017 MG132 plus apoptosis antigen-1 (APO-1) antibody cooperate to restore p53 activity inducing autophagy and p53-dependent apoptosis in HPV16 E6-expressing keratinocytes. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 0-5 tumor protein p53 Homo sapiens 105-108 27766434-7 2017 Inhibition of E6-mediated p53 proteasomal degradation by MG132 resulted in the elevation of p53 protein levels and its phosphorylation in Ser46 and Ser20; the p53 protein was localized mainly at nucleus after treatment with MG132 or APO-1 plus MG132. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 224-229 tumor protein p53 Homo sapiens 92-95 27766434-7 2017 Inhibition of E6-mediated p53 proteasomal degradation by MG132 resulted in the elevation of p53 protein levels and its phosphorylation in Ser46 and Ser20; the p53 protein was localized mainly at nucleus after treatment with MG132 or APO-1 plus MG132. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 224-229 tumor protein p53 Homo sapiens 92-95 27766434-3 2017 We investigated whether in HPV16 E6-expressing keratinocytes (KE6 cells), the restoration of p53 levels mediated by MG132 and/or activation of the CD95 pathway through apoptosis antigen-1 (APO-1) antibody are responsible for the induction of apoptosis. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 116-121 tumor protein p53 Homo sapiens 93-96 27766434-7 2017 Inhibition of E6-mediated p53 proteasomal degradation by MG132 resulted in the elevation of p53 protein levels and its phosphorylation in Ser46 and Ser20; the p53 protein was localized mainly at nucleus after treatment with MG132 or APO-1 plus MG132. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 57-62 tumor protein p53 Homo sapiens 26-29 27766434-7 2017 Inhibition of E6-mediated p53 proteasomal degradation by MG132 resulted in the elevation of p53 protein levels and its phosphorylation in Ser46 and Ser20; the p53 protein was localized mainly at nucleus after treatment with MG132 or APO-1 plus MG132. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 57-62 tumor protein p53 Homo sapiens 92-95 27766434-7 2017 Inhibition of E6-mediated p53 proteasomal degradation by MG132 resulted in the elevation of p53 protein levels and its phosphorylation in Ser46 and Ser20; the p53 protein was localized mainly at nucleus after treatment with MG132 or APO-1 plus MG132. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 57-62 tumor protein p53 Homo sapiens 92-95 27766434-7 2017 Inhibition of E6-mediated p53 proteasomal degradation by MG132 resulted in the elevation of p53 protein levels and its phosphorylation in Ser46 and Ser20; the p53 protein was localized mainly at nucleus after treatment with MG132 or APO-1 plus MG132. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 224-229 tumor protein p53 Homo sapiens 26-29 26756900-6 2016 Nutlin-3alpha or MG132 abolished the suppressive effect of a COX-2 inhibitor on DOX-induced p53 increase. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 17-22 tumor protein p53 Homo sapiens 92-95 27611480-11 2016 The proteasomal inhibitor MG-132 caused p53 protein to increase, but it had no effect on cyclin E2 protein levels. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 26-32 tumor protein p53 Homo sapiens 40-43 24691740-9 2014 P-gp and NF-kappaB significantly decreased; however, p53 increased in FaDu/T + MG132 cells. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 79-84 tumor protein p53 Homo sapiens 53-56 27473386-6 2016 Apigenin attenuated the proteasome inhibitors (MG132 and MG115)-induced decrease in the levels of Bid and Bcl-2, increase in the levels of Bax and p53, loss of the mitochondrial transmembrane potential, release of cytochrome c, activation of caspases (-8, -9 and -3), cleavage of PARP-1 and cell death in both cell lines. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 47-52 tumor protein p53 Homo sapiens 147-150 27069137-7 2016 Degradation of p53 protein by silencing PANDA was prevented by treatment of MG132, a proteasome inhibitor. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 76-81 tumor protein p53 Homo sapiens 15-18 25384678-8 2015 MG132, a specific inhibitor of the 26S proteasome, could block the effect of p53 on 14-3-3gamma protein levels, suggesting that p53 suppressed 14-3-3gamma by stimulating the process of proteasome-mediated degradation of 14-3-3gamma. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 0-5 tumor protein p53 Homo sapiens 77-80 25384678-8 2015 MG132, a specific inhibitor of the 26S proteasome, could block the effect of p53 on 14-3-3gamma protein levels, suggesting that p53 suppressed 14-3-3gamma by stimulating the process of proteasome-mediated degradation of 14-3-3gamma. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 0-5 tumor protein p53 Homo sapiens 128-131 26987571-6 2016 Moreover, the tumors treated with MG132/m showed higher levels of tumor suppressing proteins, hScrib and p53, as well as apoptotic degree, than tumors treated with free MG132. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 34-39 tumor protein p53 Homo sapiens 105-108 24691740-11 2014 MG132 was also able to inhibit the nuclear translocation of NF-kappaB and increase the expression of p53. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 0-5 tumor protein p53 Homo sapiens 101-104 23994832-4 2013 When cells were treated with a proteasome inhibitor (MG132) or an MDM2 antagonist (Nutlin-3), p53 expression was not reduced in N protein-overexpressed cells. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 53-58 tumor protein p53 Homo sapiens 94-97 23750283-7 2013 Additionally, tumor angiogenesis was inhibited, and p53 protein levels were augmented, by intratumoral injection of the ubiquitin-proteasome inhibitor MG132. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 151-156 tumor protein p53 Homo sapiens 52-55 23998584-2 2013 Apoptosis of HL-60 cells was detected by flow cytometry, the expression of P21, P27 and P53 proteins in HL-60 cells treated with MG132 was assayed by Western blot. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 129-134 tumor protein p53 Homo sapiens 88-91 23416168-9 2013 Treatment of NRCM with proteasome inhibitor MG132 increased p53 and miR-34a levels and reduced BLC2/BAX ratio. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 44-49 tumor protein p53 Homo sapiens 60-63 23470959-8 2013 In MCF-7 cells, depletion of DDX3 reduced by more than 50% camptothecin-induced p53 accumulation, and this effect was blocked by inhibition of the proteasome with MG132, indicating that DDX3 regulates p53 not at expression level but rather its stabilization after DNA damage. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 163-168 tumor protein p53 Homo sapiens 201-204 22474335-6 2012 The ladders of polyubiquitinated p53 were not detectable in the presence of the proteasome inhibitor MG132 and were less sensitive to proteasome-mediated degradation. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 101-106 tumor protein p53 Homo sapiens 33-36 22509835-5 2012 The decrease in the p53 protein by QUE/As(+3) was reversed by adding the proteasome inhibitor, MG132. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 95-100 tumor protein p53 Homo sapiens 20-23 22227409-7 2012 In addition, treatment with MG132 blocked MDM2-mediated p53 ubiquitination and degradation, and led to accumulation of p53 in Gli3 siRNA-overexpressing cells. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 28-33 tumor protein p53 Homo sapiens 56-59 22227409-7 2012 In addition, treatment with MG132 blocked MDM2-mediated p53 ubiquitination and degradation, and led to accumulation of p53 in Gli3 siRNA-overexpressing cells. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 28-33 tumor protein p53 Homo sapiens 119-122 22120628-10 2011 Both Velcade and MG132 increased the protein levels of DR5, a TRAIL receptor known to be up-regulated by p53, in U373MG cells where p53 is mutated. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 17-22 tumor protein p53 Homo sapiens 105-108 21964832-8 2012 We observed that TPA-induced down-regulation of p53 protein was prevented by ALLN and MG132, but not by chloroquine. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 98-103 tumor protein p53 Homo sapiens 60-63 23139858-6 2012 This phenotypic change was completely reversed by p53 reactivation via treatment with proteasome inhibitor MG132 or co-knockdown of E3 ligase HDM2 and partially suppressed by ATP treatment. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 107-112 tumor protein p53 Homo sapiens 50-53 22489690-8 2012 Expression of phospho-Akt and p53 showed no detectable change during the first 48 h. Pretreatment with the NF-kappaB inhibitor MG132 before exposure to isorhamnetin blocked the nuclear accumulation of p50 and p65, thereby inhibiting cell proliferation. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 127-132 tumor protein p53 Homo sapiens 30-33 22120628-10 2011 Both Velcade and MG132 increased the protein levels of DR5, a TRAIL receptor known to be up-regulated by p53, in U373MG cells where p53 is mutated. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 17-22 tumor protein p53 Homo sapiens 132-135 22031102-4 2011 Blockage of apoptosis by MG132 correlates with p53 stabilization and upregulation of p21/WAF1, a p53 transcriptional target. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 25-30 tumor protein p53 Homo sapiens 47-50 22031102-4 2011 Blockage of apoptosis by MG132 correlates with p53 stabilization and upregulation of p21/WAF1, a p53 transcriptional target. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 25-30 tumor protein p53 Homo sapiens 97-100 21619452-10 2011 Inhibition of proteosome function with MG-132 reversed the inhibitory effect of cAMP on p53. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 39-45 tumor protein p53 Homo sapiens 88-91 21262221-4 2011 Moreover, inducing p53 accumulation with MG132 reduced autophagic ratio, and repressed the expression and activation of NF-kappaB expression. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 41-46 tumor protein p53 Homo sapiens 19-22 21224072-4 2011 We found that well-known proteasome inhibitors such as MG132 and bortezomib, as well as the recently discovered proteasome inhibitor thiostrepton, induced p53-independent apoptosis in human cancer cell lines that correlated with p53-independent induction of proapoptotic Noxa but not Puma protein. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 55-60 tumor protein p53 Homo sapiens 155-158 21167122-6 2011 Treatment of 8B20 cells with the UPP inhibitors, MG132 and clasto-lactacystin-beta-lactone, led to an increase in levels of p53 while treatment with non-proteasomal inhibitors did not alter p53 levels. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 49-54 tumor protein p53 Homo sapiens 124-127 21167122-9 2011 Treatment of 8B20 cells with MG132 led to an increase in the half-life of p53. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 29-34 tumor protein p53 Homo sapiens 74-77 21167122-11 2011 In vivo studies showed that MG132 induced p53 overexpression and reduced tumor growth, suggesting an important role of p53 stabilization in controlling melanoma. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 28-33 tumor protein p53 Homo sapiens 42-45 21167122-11 2011 In vivo studies showed that MG132 induced p53 overexpression and reduced tumor growth, suggesting an important role of p53 stabilization in controlling melanoma. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 28-33 tumor protein p53 Homo sapiens 119-122 21268072-7 2011 Furthermore, inhibition of proteasome activity by MG132 blocked GA-induced down-regulation of mutant p53, causing mutant p53 accumulation in detergent-insoluble cellular fractions. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 50-55 tumor protein p53 Homo sapiens 101-104 21268072-7 2011 Furthermore, inhibition of proteasome activity by MG132 blocked GA-induced down-regulation of mutant p53, causing mutant p53 accumulation in detergent-insoluble cellular fractions. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 50-55 tumor protein p53 Homo sapiens 121-124 21224072-4 2011 We found that well-known proteasome inhibitors such as MG132 and bortezomib, as well as the recently discovered proteasome inhibitor thiostrepton, induced p53-independent apoptosis in human cancer cell lines that correlated with p53-independent induction of proapoptotic Noxa but not Puma protein. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 55-60 tumor protein p53 Homo sapiens 229-232 20332106-5 2010 When cells were treated with the proteasome inhibitor MG132, the size and frequency of p53-containing nucleolar cavities increased, and the protein partially colocalized with inactivated proteasomes. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 54-59 tumor protein p53 Homo sapiens 87-90 20840860-7 2010 Treatment of the cells with the proteasome inhibitor MG-132 resulted in the accumulation of both p53 and PPP1R13L proteins. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 53-59 tumor protein p53 Homo sapiens 97-100 19699254-5 2009 The proteasome inhibitor MG132 completely blocked capsaicin-induced p53 degradation and enhanced apoptotic cell death. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 25-30 tumor protein p53 Homo sapiens 68-71 19033390-3 2008 We recently showed that p53 localizes to the nucleolus after proteasome inhibition with MG132 and this localization requires sequences within its carboxyl terminus. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 88-93 tumor protein p53 Homo sapiens 24-27 18951928-5 2009 We show that Zn/PDTC induces p53 proteasomal degradation and that the proteasome inhibitor MG132 further increases fibroblast growth inhibition by Zn/PDTC, suggesting that p53 degradation plays an important role in fibroblast resistance to Zn/PDTC. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 91-96 tumor protein p53 Homo sapiens 172-175 19033390-4 2008 In the present study, we found that after treatment with MG132, p53 associates with a discrete sub-nucleolar component, the fibrillar center (FC), a region mainly enriched with RNA polymerase I. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 57-62 tumor protein p53 Homo sapiens 64-67 15567145-5 2005 The ubiquitination and destabilization of p53 is observed in cells treated with the protease inhibitor MG132, implying that the HECT domain of hUREB1 suppresses the transcriptional activity of p53 through a ubiquitin-dependent degradation pathway. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 103-108 tumor protein p53 Homo sapiens 42-45 18523266-7 2008 The protein stability, Ser(392) phosphorylation and Lys(373)/Lys(382) acetylation of p53 were enhanced by MG132. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 106-111 tumor protein p53 Homo sapiens 85-88 18523266-10 2008 Intracellular reactive oxygen species (ROS) generation after MG132 treatment contributed to p53, but not p65 nuclear translocation and DNA-binding activity. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 61-66 tumor protein p53 Homo sapiens 92-95 18283158-4 2008 RESULTS: In cells that express E6, proteasome inhibition with MG132 restored p53 protein levels and decreased proliferation in a dose-dependent fashion that was significantly more pronounced compared with controls. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 62-67 tumor protein p53 Homo sapiens 77-80 17698841-8 2007 HDM2 was stabilized in the HCMV-infected cells by MG132, indicating a shift from p53 to HDM2 ubiquitination. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 50-55 tumor protein p53 Homo sapiens 81-84 17224908-6 2007 Proteasome inhibition by MG132 increases the occupancy of p53 protein at p53-responsive p21(waf1) promoter. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 25-30 tumor protein p53 Homo sapiens 58-61 17224908-6 2007 Proteasome inhibition by MG132 increases the occupancy of p53 protein at p53-responsive p21(waf1) promoter. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 25-30 tumor protein p53 Homo sapiens 73-76 16673057-0 2006 MG132 induced apoptosis is associated with p53-independent induction of pro-apoptotic Noxa and transcriptional activity of beta-catenin. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 0-5 tumor protein p53 Homo sapiens 43-46 16673057-10 2006 In summary, our results demonstrate that MG132 induces the pro-apoptotic protein Noxa via a p53-independent mechanism that leads to caspase-dependent apoptosis. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 41-46 tumor protein p53 Homo sapiens 92-95 15567145-5 2005 The ubiquitination and destabilization of p53 is observed in cells treated with the protease inhibitor MG132, implying that the HECT domain of hUREB1 suppresses the transcriptional activity of p53 through a ubiquitin-dependent degradation pathway. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 103-108 tumor protein p53 Homo sapiens 193-196 15147952-4 2004 Using the proteasome-specific inhibitors, MG132 and lactacystin, we show that the p53, the cdk inhibitors p21 and p27, and cyclin A are degraded by the ubiquitin-proteasome pathway in human osteosarcoma cells. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 42-47 tumor protein p53 Homo sapiens 82-85 12655090-7 2003 Both HTLV-I Tax and the proteasome-specific inhibitor MG132 inhibited p53-mediated TRX protein degradation. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 54-59 tumor protein p53 Homo sapiens 70-73 15010833-6 2004 MG132 treated HCT116 (wild-type) had a similar cell cycle distribution as the MG132 treated HCT116 (p53-/-) and HCT116 (p21-/-) cells, suggesting that p53 and p21 may not be essential for MG132-induced G2/M phase arrest. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 0-5 tumor protein p53 Homo sapiens 151-154 15010833-6 2004 MG132 treated HCT116 (wild-type) had a similar cell cycle distribution as the MG132 treated HCT116 (p53-/-) and HCT116 (p21-/-) cells, suggesting that p53 and p21 may not be essential for MG132-induced G2/M phase arrest. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 78-83 tumor protein p53 Homo sapiens 100-103 15010833-6 2004 MG132 treated HCT116 (wild-type) had a similar cell cycle distribution as the MG132 treated HCT116 (p53-/-) and HCT116 (p21-/-) cells, suggesting that p53 and p21 may not be essential for MG132-induced G2/M phase arrest. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 78-83 tumor protein p53 Homo sapiens 100-103 15010833-5 2004 MG132 arrested HCT116 cells at G2/M phase, which was associated with drug-induced blockade of p53 degradation and/or induction of p53-related gene expression along with the accumulation of cyclin B, cyclin A and p21. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 0-5 tumor protein p53 Homo sapiens 94-97 15010833-5 2004 MG132 arrested HCT116 cells at G2/M phase, which was associated with drug-induced blockade of p53 degradation and/or induction of p53-related gene expression along with the accumulation of cyclin B, cyclin A and p21. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 0-5 tumor protein p53 Homo sapiens 130-133 14700734-3 2004 The proteasome inhibitor, MG132, induced the accumulation of p53 in human dopaminergic neuroblastoma SH-SY5Y cells. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 26-31 tumor protein p53 Homo sapiens 61-64 12640129-6 2003 Treatment of MCF10A cells with MG132, a 26S proteasome inhibitor, effectively stabilized monoubiquitinated p53 and rescued ADR-induced downregulation of Hdm2. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 31-36 tumor protein p53 Homo sapiens 107-110 12372430-2 2002 In this report, upon exposure of cells to ultraviolet (UV) or proteasome inhibitor MG132, ATF3 protein was induced more efficiently in cells with intact p53 allele than in those with null mutant p53 allele. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 83-88 tumor protein p53 Homo sapiens 153-156 12610816-10 2003 The expression of the p53 response proteins, MDM2 and p21, was elevated in MG132 treated chondrocytes. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 75-80 tumor protein p53 Homo sapiens 22-25 12372430-2 2002 In this report, upon exposure of cells to ultraviolet (UV) or proteasome inhibitor MG132, ATF3 protein was induced more efficiently in cells with intact p53 allele than in those with null mutant p53 allele. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 83-88 tumor protein p53 Homo sapiens 195-198 11161273-12 2001 EBNA-5 also enhanced the nucleolar translocation of a mutant p53 in a colon cancer line, SW480, treated with MG132. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 109-114 tumor protein p53 Homo sapiens 61-64 11840331-4 2002 This p53wt diminution was dependent on proteasome activity, as inhibited by MG-132 inhibitor. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 76-82 tumor protein p53 Homo sapiens 5-8 11329373-4 2001 Immunocytochemistry of fixed human fibroblasts treated with either UV light, the kinase and transcription inhibitor DRB or the proteasome inhibitor MG132 revealed abundant p53 localized to the nucleus. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 148-153 tumor protein p53 Homo sapiens 172-175 11329373-6 2001 However, in cells treated with MG132, residual p53 localized to distinct large foci. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 31-36 tumor protein p53 Homo sapiens 47-50 12127985-6 2002 MG132 or actinomycin D both led to a significant increase in p53, but the expressions of the p53 response proteins increased only in MG132 treated chondrocytes. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 0-5 tumor protein p53 Homo sapiens 61-64 12127985-6 2002 MG132 or actinomycin D both led to a significant increase in p53, but the expressions of the p53 response proteins increased only in MG132 treated chondrocytes. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 133-138 tumor protein p53 Homo sapiens 93-96 11803460-8 2002 CD95-resistant HPV-positive cells underwent apoptosis within 3-5 h upon co-incubation with MG132 and agonistic antibodies or CD95 ligand, which was preceded by a strong re-expression of p53 and c-Myc, but not of other half-life controlled proteins such as Bax or IkappaBalpha. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 91-96 tumor protein p53 Homo sapiens 186-189 11477551-4 2001 Gastric cancer cell lines AGS (p53 wild-type) and MKN-28 (p53 mutant) were treated with proteasome inhibitor MG132. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 109-114 tumor protein p53 Homo sapiens 58-61 11161273-13 2001 The coordinated changes in EBNA-5 and Hsp70 localization and the effect of EBNA-5 on mutant p53 distribution upon MG132 treatment might reflect the involvement of EBNA-5 in the regulation of intracellular protein trafficking associated with the proteasome-mediated degradation. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 114-119 tumor protein p53 Homo sapiens 92-95 11158615-6 2001 This reduction was prevented by the proteasome inhibitors MG132 and lactacystin, suggesting enhanced p53 degradation in the presence of dicoumarol. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 58-63 tumor protein p53 Homo sapiens 101-104 9266962-0 1997 Transcriptional squelching by ectopic expression of E2F-1 and p53 is alleviated by proteasome inhibitors MG-132 and lactacystin. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 105-111 tumor protein p53 Homo sapiens 62-65 10837373-8 2000 With the addition of MG-132, a proteasome inhibitor, to B[a]P or 1-NP treatments, both p21 and p53 protein levels were increased; however, the increase in p21 protein levels was significantly larger than the increase in p53 protein levels. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 21-27 tumor protein p53 Homo sapiens 95-98 10837373-8 2000 With the addition of MG-132, a proteasome inhibitor, to B[a]P or 1-NP treatments, both p21 and p53 protein levels were increased; however, the increase in p21 protein levels was significantly larger than the increase in p53 protein levels. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 21-27 tumor protein p53 Homo sapiens 220-223 9438391-2 1998 Using the proteasome-specific inhibitors, MG132 (N-acetyl-L-leucinyl-L-leucinal-L-leucinal) and lactacystin, here we show that the p53-response proteins, bax and mdm2 as well as p21, are degraded by the ubiquitin-proteasome pathway in HeLa cells. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 42-47 tumor protein p53 Homo sapiens 131-134 9438391-3 1998 MG132 also increased expression of the three proteins in cells that lack p53, showing that stabilization of the p53 response proteins is not due to increased levels of p53 itself. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 0-5 tumor protein p53 Homo sapiens 73-76 9438391-3 1998 MG132 also increased expression of the three proteins in cells that lack p53, showing that stabilization of the p53 response proteins is not due to increased levels of p53 itself. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 0-5 tumor protein p53 Homo sapiens 112-115 9438391-3 1998 MG132 also increased expression of the three proteins in cells that lack p53, showing that stabilization of the p53 response proteins is not due to increased levels of p53 itself. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 0-5 tumor protein p53 Homo sapiens 112-115 11073163-5 2000 Induction of apoptosis by lactacystin or ZLLLal was accompanied by cell cycle arrest at G2/M phase and by accumulation and stabilization of cyclin-dependent kinase inhibitor p21WAF1/Cip and tumor suppressor protein p53. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 41-47 tumor protein p53 Homo sapiens 215-218 10891461-8 2000 In contrast, p53 was stabilized by MG132 or LLnL in malignant and normal cells undergoing apoptosis, indicating that in normal lymphocytes p53 is regulated mainly by calpains and not by the ubiquitin-proteasome system. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 35-40 tumor protein p53 Homo sapiens 13-16 10554039-12 1999 When Y79 cells were exposed to combinations of sodium butyrate and MG132, the latter compound suppressed the decreasing effect induced by sodium butyrate on the levels of p53, N-myc, and IkappaBalpha and the increasing effect on the nuclear level of nuclear factor kappaB. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 67-72 tumor protein p53 Homo sapiens 171-174 9266962-4 1997 Several observations indicate MG-132 alleviates squelching by influencing the conformation of newly synthesized p53 and E2F-1:MG-132 increased the fraction of wild type p53 bound by a monoclonal antibody which preferentially recognizes mutant conformers of p53, increased binding of hsp70 to p53 and inhibited nuclear accumulation of both p53 and E2F-1, but not the pocket protein p107. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 126-132 tumor protein p53 Homo sapiens 112-115 9266962-4 1997 Several observations indicate MG-132 alleviates squelching by influencing the conformation of newly synthesized p53 and E2F-1:MG-132 increased the fraction of wild type p53 bound by a monoclonal antibody which preferentially recognizes mutant conformers of p53, increased binding of hsp70 to p53 and inhibited nuclear accumulation of both p53 and E2F-1, but not the pocket protein p107. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 126-132 tumor protein p53 Homo sapiens 169-172 9266962-4 1997 Several observations indicate MG-132 alleviates squelching by influencing the conformation of newly synthesized p53 and E2F-1:MG-132 increased the fraction of wild type p53 bound by a monoclonal antibody which preferentially recognizes mutant conformers of p53, increased binding of hsp70 to p53 and inhibited nuclear accumulation of both p53 and E2F-1, but not the pocket protein p107. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 126-132 tumor protein p53 Homo sapiens 169-172 9266962-4 1997 Several observations indicate MG-132 alleviates squelching by influencing the conformation of newly synthesized p53 and E2F-1:MG-132 increased the fraction of wild type p53 bound by a monoclonal antibody which preferentially recognizes mutant conformers of p53, increased binding of hsp70 to p53 and inhibited nuclear accumulation of both p53 and E2F-1, but not the pocket protein p107. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 126-132 tumor protein p53 Homo sapiens 169-172 9266962-4 1997 Several observations indicate MG-132 alleviates squelching by influencing the conformation of newly synthesized p53 and E2F-1:MG-132 increased the fraction of wild type p53 bound by a monoclonal antibody which preferentially recognizes mutant conformers of p53, increased binding of hsp70 to p53 and inhibited nuclear accumulation of both p53 and E2F-1, but not the pocket protein p107. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 126-132 tumor protein p53 Homo sapiens 169-172 9266962-6 1997 Because MG-132 and lactacycstin are highly specific inhibitors of the proteasome protease, our results suggest that the proteasome influences post-translational processes involved in proper folding and cytoplasmic clearing of E2F-1 and p53. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 8-14 tumor protein p53 Homo sapiens 236-239 9266962-3 1997 Although the proteasome inhibitors MG-132 and lactacystin markedly increased the level of expression of E2F-1 and p53, these inhibitors completely alleviated squelching by both proteins. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 35-41 tumor protein p53 Homo sapiens 114-117 9266962-4 1997 Several observations indicate MG-132 alleviates squelching by influencing the conformation of newly synthesized p53 and E2F-1:MG-132 increased the fraction of wild type p53 bound by a monoclonal antibody which preferentially recognizes mutant conformers of p53, increased binding of hsp70 to p53 and inhibited nuclear accumulation of both p53 and E2F-1, but not the pocket protein p107. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 30-36 tumor protein p53 Homo sapiens 112-115 9266962-4 1997 Several observations indicate MG-132 alleviates squelching by influencing the conformation of newly synthesized p53 and E2F-1:MG-132 increased the fraction of wild type p53 bound by a monoclonal antibody which preferentially recognizes mutant conformers of p53, increased binding of hsp70 to p53 and inhibited nuclear accumulation of both p53 and E2F-1, but not the pocket protein p107. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 30-36 tumor protein p53 Homo sapiens 169-172 9266962-4 1997 Several observations indicate MG-132 alleviates squelching by influencing the conformation of newly synthesized p53 and E2F-1:MG-132 increased the fraction of wild type p53 bound by a monoclonal antibody which preferentially recognizes mutant conformers of p53, increased binding of hsp70 to p53 and inhibited nuclear accumulation of both p53 and E2F-1, but not the pocket protein p107. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 30-36 tumor protein p53 Homo sapiens 169-172 9266962-4 1997 Several observations indicate MG-132 alleviates squelching by influencing the conformation of newly synthesized p53 and E2F-1:MG-132 increased the fraction of wild type p53 bound by a monoclonal antibody which preferentially recognizes mutant conformers of p53, increased binding of hsp70 to p53 and inhibited nuclear accumulation of both p53 and E2F-1, but not the pocket protein p107. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 30-36 tumor protein p53 Homo sapiens 169-172 9266962-4 1997 Several observations indicate MG-132 alleviates squelching by influencing the conformation of newly synthesized p53 and E2F-1:MG-132 increased the fraction of wild type p53 bound by a monoclonal antibody which preferentially recognizes mutant conformers of p53, increased binding of hsp70 to p53 and inhibited nuclear accumulation of both p53 and E2F-1, but not the pocket protein p107. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 30-36 tumor protein p53 Homo sapiens 169-172 16287099-8 2006 Inhibition of E6-mediated p53 proteasomal degradation by MG132 resulted in elevated levels of active p53 as demonstrated by p53 small interfering RNA (siRNA) sensitive p21 upregulation. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 57-62 tumor protein p53 Homo sapiens 26-29 16287099-8 2006 Inhibition of E6-mediated p53 proteasomal degradation by MG132 resulted in elevated levels of active p53 as demonstrated by p53 small interfering RNA (siRNA) sensitive p21 upregulation. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 57-62 tumor protein p53 Homo sapiens 101-104 16287099-8 2006 Inhibition of E6-mediated p53 proteasomal degradation by MG132 resulted in elevated levels of active p53 as demonstrated by p53 small interfering RNA (siRNA) sensitive p21 upregulation. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 57-62 tumor protein p53 Homo sapiens 101-104 16287099-9 2006 Although p53 siRNA partially inhibited MG132-induced DR5 upregulation in HeLa and SiHa, no effect on rhTRAIL-induced apoptosis was observed. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 39-44 tumor protein p53 Homo sapiens 9-12 33824292-10 2021 The results of the CHX-chase experiment showed that depletion of RNF31 alleviated p53 degradation, which was inhibited by MG132. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 122-127 tumor protein p53 Homo sapiens 82-85 33767588-6 2021 Delivery of the proteasome inhibitor, MG132, reversed the inhibitory effect of miR-26b on the level of p53 following doxorubicin treatment. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 38-43 tumor protein p53 Homo sapiens 103-106